pharma · Hemorrhoids · Persistent or Recurrent Cutaneous T-Cell Lymphoma · CTOR
CITIUS ONCOLOGY
CITIUS ONCOLOGY, INC.
Citius Oncology is a pharma organization headquartered in Cranford, USA. It trades on NYSE under ticker CTOR. Primary therapeutic focus areas include Hemorrhoids, Persistent or Recurrent Cutaneous T-Cell Lymphoma. NovaPh
Cranford, USA HQ
2024 Founded
5 Employees
Public company Type
CTOR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cranford, USA
- Founded
- 2024
- Employees
- 5
- Programs
- 3
- Drugs
- 8
- Patents
- 0
Monad 1
Phase 2 · small molecule · Hemorrhoids
Monad 1 for Hemorrhoids is a Phase 2 program (small_molecule) at CITIUS ONCOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Internal code 143-11351-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CITIUS ONCOLOGY, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hemorrhoids
- Status
- completed
- Trials
- 1